Investors Are Craving More from ZIOPHARM Oncology Inc. [ZIOP] Stocks: Here is Why

ZIOPHARM Oncology Inc. [ZIOP] stock is down -3.53 while the S&P 500 has fallen -0.17% on Friday, 12/04/20. While at the time of this article, ZIOP ATR is sitting at 0.15, with the beta value at 2.27. This stock’s volatility for the past week remained at 4.88%, while it was 6.10% for the past 30-day period. ZIOP has fallen -$0.1 from the previous closing price of $2.83 on volume of 0.81 million shares.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


On 4, December 2020, Ziopharm Details Actions in Response to Shareholder Feedback. According to news published on Yahoo Finance, Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation.

Analyst Birdseye View:

The most recent analyst activity for ZIOPHARM Oncology Inc. [NASDAQ:ZIOP] stock was on March 04, 2020, when it was Initiated with an Overweight rating from Cantor Fitzgerald, which also raised its 12-month price target on the stock to $6. Before that, on June 19, 2020, Jefferies Recapitulated a Buy rating and elevated its amount target to $7. On August 23, 2019, Raymond James Resumed an Outperform rating. On April 04, 2019, Lake Street Initiated a Buy rating and increased its price target to $7. On April 01, 2019, Laidlaw Initiated a Buy rating and increased its price target to $7.50. On November 15, 2018, Raymond James Upgrade an Outperform rating. On June 18, 2018, JP Morgan Downgrade an Underweight rating. On June 01, 2017, H.C. Wainwright Initiated a Buy rating and amplified its amount target to $9.50.

In the past 52 weeks of trading, this stock has oscillated between a low of $1.79 and a peak of $5.61. Right now, according to Wall Street analyst the average 12-month amount target is $5.93. At the most recent market close, shares of ZIOPHARM Oncology Inc. [NASDAQ:ZIOP] were valued at $2.73.


The Principal structure of this organization shows its whole liability to whole principal at 2.42 and the whole liability to whole assets at 2.16. It shows enduring liability to the whole principal at 1.62 and enduring liability to assets at 0.01 while looking for an extended time period.

Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 2.76 points at 1st support level, the second support level is making up to 2.68. But as of 1st resistance point, this stock is sitting at 2.89 and at 2.95 for 2nd resistance point.

ZIOPHARM Oncology Inc. [ZIOP] reported its earnings at -$0.1 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.09/share signifying the difference of -0.01 and -11.10% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.09 calling estimates for -$0.09/share with the difference of 0 depicting the surprise of 0.00%.

Important Ratio’s To Watch

Meanwhile, turning our focus to liquidity, the Current Ratio for ZIOPHARM Oncology Inc. [NASDAQ:ZIOP] is 8.00. Likewise, the Quick ratio is also the same, showing Cash ratio at 6.37. Now if looking for a valuation of this stock’s amount to book ratio is 9.03.

Insider Stories

The most recent insider trade was by MAUNEY DAVID M MD, President, and it was the sale of 22394.0 shares on Jan 02. Lafond Kevin G, the SVP, Treasurer & CAO, completed a sale of 21570.0 shares on Jan 02. On Jan 02, Hadfield Robert, General Counsel and Secretary, completed a sale of 16853.0 shares.